Escherichia Coli Infection
4
0
0
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
6 treatments under study, led by Modified E Coli Heat Labile Enterotoxin Ltr192g
Research Leaders
9 sponsors active, led by U.S. Army Medical Research and Development Command
Related Conditions
Often studied with 8 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 4 trials
100.0%
+13.4% vs benchmark
50%
2 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (4)
Oral Fosfomycin as Sequential Oral Treatment for Multidrug-Resistant Escherichia Coli in Acute Bacterial Prostatitis
Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing Enterobacteriaceae
Safety Study of Chimeric Vaccine to Prevent ETEC Diarrhea
Safety Study of Recombinant Vaccine to Prevent ETEC Diarrhea
Research Network
Common Treatments
- Modified E Coli Heat Labile Enterotoxin Ltr192g2
- Recombinant Fimbrial Adhesin Dsccfae2
- Meropenem1
- Ertapenem1
- Recombinant Fimbrial Adhesin Dsc14cfaescta2ltb51
Active Sponsors
- U.S. Army Medical Research and Development Command2
- Clinica Universidad de Navarra, Universidad de Navarra1
- Parc Taulí Hospital Universitari1
- Hospital Mutua de Terrassa1
- Hospital del Mar1
Top Investigators
Naval Medical Research Center
Enteric Diseases Department, Naval Medical Research Center
Universidad del Norte´s Hospital-Infectious Diseases.
Universidad del Norte
Related Conditions
- Prostatitis1
- Carbapenem1
- Enterobacteriaceae Infections1
- Klebsiella Pneumoniae Infection1
- Urinary Tract Infections1